Advances in mitochondrial-targeted colorectal cancer therapy: Mechanistic insights and clinical translation

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Colorectal cancer (CRC) therapy is challenged by drug resistance and limited treatment efficacy. Mounting evidence now positions mitochondrial dysfunction as a central mediator of these challenges, making it a compelling therapeutic target. This review synthesizes findings demonstrating that targeting mitochondrial metabolism, apoptosis, dynamics, mitophagy, and intercellular transfer effectively overcomes chemoresistance and restores treatment sensitivity in CRC models. Key mechanisms include the reversal of the Warburg effect, reactivation of intrinsic apoptosis, and disruption of mitochondrial transfer. Clinically, mitochondrial-derived biomarkers, such as cell-free mtDNA, emerge as promising tools for non-invasive monitoring and prognosis. Furthermore, advancements in targeted delivery systems and supportive interventions such as exercise, are shown to enhance therapeutic efficacy and mitigate toxicity. We conclude that integrating mitochondrial-targeted strategies represents a transformative approach for CRC treatment, with future success hinging on overcoming delivery challenges and validating these strategies in personalized models.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.